Related Experiment Video
Updated: May 12, 2026

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
Published on: July 8, 2020
Application of the updated International IgA Nephropathy Prediction Tool in children one or two years post-biopsy
Sean J Barbour1, Rosanna Coppo2, Lee Er3
1Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada; BC Renal, Vancouver, British Columbia, Canada.
Insights
The updated pediatric International IgA Nephropathy (IgAN) Prediction Tool accurately predicts kidney function decline one year post-biopsy. This tool aids in re-evaluating IgAN risk in children over time.
Area of Science:
- Nephrology
- Pediatric Nephrology
- Clinical Prediction Modeling
Background:
- The International IgA Nephropathy (IgAN) Prediction Tool assesses pediatric kidney disease risk at biopsy.
- Its utility for re-evaluation post-biopsy in children remains unestablished.
Purpose of the Study:
- To update and validate the pediatric IgAN Prediction Tool for use one year after kidney biopsy.
- To assess the tool's performance in predicting estimated glomerular filtration rate (eGFR) decline or kidney failure.
Main Methods:
- An international cohort of 947 children with IgAN was used.
- The original pediatric IgAN Prediction Tool was updated for one-year post-biopsy assessment.
- Model fit, C-statistics, and calibration were compared between the original and updated tools.
Main Results:
- The updated post-biopsy tool demonstrated superior model fit (R²D 51%/50% vs 20%) and significantly improved 4-year predictive accuracy (C-statistics 0.83 vs 0.73/0.69).
- Calibration was better with the updated tool (ICI 0.74/0.54 vs 2.45/1.01).
- Higher predicted risk correlated with lower baseline eGFR and faster decline, irrespective of age.
Conclusions:
- The updated pediatric IgAN Prediction Tool is effective for re-evaluating IgAN risk one to two years post-biopsy.
- The original tool is recommended at biopsy; the updated tool is for subsequent risk reassessment in pediatric IgAN patients.
Abstract:
The pediatric International IgA Nephropathy (IgAN) Prediction Tool comprises two models with and without ethnicity and is the first method to predict the risk of a 30% decline in estimated glomerular filtration rate (eGFR) or kidney failure in children at the time of biopsy using clinical risk factors and Oxford MEST histology scores. However, it is unknown if the Prediction Tool can be applied after a period of observation post-biopsy. Using an international multi-ethnic cohort of 947 children with IgAN, 38% of whom were followed into adulthood, the Prediction Tool was updated for use one year after biopsy. Compared to the original pediatric Prediction Tool, the updated post-biopsy Prediction Tool had a better model fit with higher R2D (51%/50% vs 20%), significant increase in 4-year C-statistics (0.83 vs 0.73/0.69, ΔC 0.09 [95% confidence interval 0.07-0.10] and ΔC 0.14 [0.12-0.15]) and better 4-year calibration with lower integrated calibration indices (0.74/0.54 vs 2.45/1.01). Results were similar after internal validation and when the models were applied two years after biopsy. Trajectories of eGFR after a baseline one year post-biopsy were non-linear and those at higher predicted risk started with a lower eGFR and experienced a more rapid decline over time. In children, eGFR had a variable rate of increase until 15-18 years old and then decreased linearly with a more rapid decline in higher risk groups that was similar to young adults of comparable risk. Thus, the original pediatric Prediction Tool should be used in children at the time of biopsy, and the updated pediatric Prediction Tool should be used to re-evaluate risk one or two years after biopsy.
Related Concept Videos
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Kidney Transplant I: Introduction
Acute Kidney Injury I: Introduction
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Chronic Kidney Disease III: Interprofessional Care

